Plain-English translation of NCT06860971 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Thyroid Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called AL2846 to see if it can help people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed despite other targeted therapies. You would take the medication (or a placebo) in 28-day cycles to see if it slows or stops cancer growth. The study involves about 144 patients across multiple centers.
People with advanced thyroid cancer that no longer responds to radioactive iodine have limited treatment options, especially after other targeted therapies stop working. This trial is testing whether this new treatment can extend the time before cancer progresses and help improve outcomes for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication AL2846 or a placebo (a pill with no active ingredient), taken in 28-day treatment cycles. You will visit the study center regularly for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and any side effects. The study involves about 144 patients, and neither you nor your doctor will know which treatment you are receiving until the study ends.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China